Latest Kaiser Health News Stories
California and federal officials have cracked down on a major compounding pharmacy they say posed a threat to public safety, but their actions are worsening shortages of medications that doctors rely on to keep their patients out of pain.
Suffering Americans seek medical marijuana as an alternative to opioids and other powerful pharmaceuticals. Though legal in 29 states, some doctors say the lack of strong data makes it hard to recommend.
Kaiser Health News reporter Sarah Jane Tribble sat down with Food and Drug Administration Commissioner Scott Gottlieb on C-SPAN’s “Newsmakers” program. The conversation ranged from how the nation should combat the opioid epidemic to reining in drug prices.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Margot Sanger-Katz of The New York Times discuss the apparent demise of bipartisan legislation aimed at shoring up parts of the Affordable Care Act. They also discuss aggressive new efforts by the Food and Drug Administration to regulate tobacco products. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
In a historic move, the Food and Drug Administration stated its intent Thursday to require tobacco companies to cut nicotine levels in their products to make them less addictive. Stripping cigarettes of addictive power could lead an estimated 5 million adults to quit smoking within a year of the plan.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
The Republican senator sent out letters to the Food and Drug Administration and HHS demanding an explanation about a rogue herpes vaccine trial.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Controversial research methods by university researcher unlikely to prompt federal response or institutional change, experts say.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.
The federal agents warned store owners that importing drugs from foreign countries is illegal and that those helping “administer” such medicines could face penalties.
Agency says a removable cap will lower the risk of antibiotic resistant infections but some experts see it as a modest step in curbing the sort of deadly outbreaks that occurred a few years ago.
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
In a head-to-head comparison, several of the cheaper devices performed nearly as well as the expensive hearing aids. The study lends credence to lawmakers’ efforts to get the FDA to set standards for over-the-counter versions.
Innate Immunotherapeutics, whose largest shareholder is Buffalo-area Rep. Chris Collins, received FDA approval to begin U.S. trials of its drug for treating advanced multiple sclerosis.
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, “black box” warnings or other actions.
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.